Do you know what…?
Why can HIV prevention leave the daily pill behind, but not regular care?
AI-generated image, not a photograph. This edition's article, audio and test are AI-generated and published automatically without prior human review. Sources · Editorial & AI Policy
Listen to today’s article
HIV prevention can be difficult to sustain when it requires a daily tablet, particularly where privacy, stigma or access to health care complicate the routine. Lenacapavir offers a different rhythm: long-acting prevention administered twice yearly. In July 2025, the World Health Organization recommended it as an additional pre-exposure prophylaxis option—medicine used to prevent HIV before exposure. The attraction is not simply a less crowded medication schedule. It is the possibility of easing the daily burden of . Yet moving beyond a daily pill does not mean dispensing with testing, follow-up or accessible services.
The striking evidence came from PURPOSE 1, a trial involving adolescent girls and young women in South Africa and Uganda. It compared lenacapavir administered under the skin every 26 weeks with daily oral prevention. Among the 2,134 participants assigned to lenacapavir, no new HIV infections were observed in the reported analysis. That is an extraordinary result, not a promise of universal protection. The reported incidence ran from 0.00 to 0.19 infections per 100 person-years, reflecting statistical uncertainty. The finding belongs to that study population and observation period; it does not establish how every real-world programme will perform.
Delivery is . According to the Global Fund, all nine early-adopter African countries it supported had launched lenacapavir by June 2026; nearly 100,000 people had received it by mid-August 2026 in that rollout. Those are recipients, not a measure of infections prevented. Meanwhile, WHO reported that international funding reductions during 2025 disrupted HIV services, with some community-led programmes scaled back or closed. Long-acting medicine can reduce the frequency of medication without removing the need for dependable care. The breakthrough therefore shifts part of the challenge: from sustaining a daily routine to sustaining the services that make prevention possible.
Sources (4)
- World Health Organization — recommendation on lenacapavir for HIV prevention
- New England Journal of Medicine, indexed by PubMed — PURPOSE 1 trial report
- The Global Fund — institutional reporting on HIV programmes and lenacapavir rollout
- World Health Organization — HIV prevention tools, services and funding